SynCore Biotechnology Co., Ltd (“SynCore”) is a biopharmaceutical company focusing on creating values of the new drug by R&D and integration of technology resources. SynCore was established in 2008 and cofounded by Sinphar Group and National Health Research Institute (NHRI). SynCore inherited Sinphar’s experiences which have been accumulated for more than 30 years in R&D, manufacturing, and international marketing. Such experiences enable SynCore to build up the comprehensive pipeline portfolio for new drug development to fulfill domestic and international market needs and to consolidate the future development. SynCore utilizes and in-licenses the unique technologies from all over the world to develop new drugs with great marketing potential. By professional and expeditious project management, SynCore accumulates intangible assets to promote its marketing values. SynCore keeps looking for international partners actively and guarantees stable and long-term profits through strategic alliance to enrich sustainable operating energy. The mission of the SynCore is to consolidate the drug development and innovative biotechnology of disease treatment to pursuit a better human health and society. SynCore acts in a responsible and ethical manner and with a commitment to sustainable development respecting the needs of the individual, the society, and the environment.